SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Hepatology Referral — Joe Frazier — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Joe Frazier |
|---|
| Date of birth | 1944-01-12 |
|---|
| Identifiers | MRN HR-BX004-SYN-TD; SSN (made up) 000-04-5590 |
|---|
| Document date | 2008-02-16 |
|---|
| Author | Clarence Whitfield, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
High FIB-4 (3.43) with a mildly raised AST and low platelets at the yearly liver check in a 64-year-old man with type 2 diabetes, hypertension, low HDL, high triglycerides and obesity, who drinks little. Please stage his liver disease with elastography and advise on surveillance and treatment. [S]
Urgency: Within two weeks, with elastography and an ultrasound the same day. [S]
Questions for the consultant:
- How advanced is the fibrosis, and is this MASLD?
- Does he need liver cancer surveillance, and how often?
- Does he need screening for varices or a beta-blocker?
- Which diabetes medicine would you favor for his liver, and are metformin and atorvastatin safe?
- Which vaccines and other precautions do you advise?
History of Present Illness
Former professional heavyweight boxer who runs a gym. Type 2 diabetes for about twelve years on metformin (A1c 8.4%); hypertension on lisinopril, above goal; LDL 132 mg/dL, HDL 38, triglycerides 210; BMI 31.4. Alcohol: one or two beers on some weekends (AUDIT-C 2); never smoked; no drug use. No history of jaundice, swelling or bleeding. Today: AST 48 and ALT 42 U/L, alkaline phosphatase 96, albumin 4.0 g/dL, bilirubin 0.9 mg/dL, platelets 138, hemoglobin 14.2, creatinine 1.08 mg/dL (eGFR 77), urine albumin-to-creatinine ratio 18 mg/g. FIB-4 3.43. Atorvastatin 40 mg started today. Hepatitis B, hepatitis C and HIV tests, iron studies and autoimmune tests sent. Reduced vision in the left eye since a cataract found at 20 [S]
- He wants to keep working at his gym and stay strong. [S]
- He worries about the cost of new medicines. [S]
- He wants to know whether the blows he took in the ring will affect his memory. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Joe Frazier was born on January 12, 1944, in Beaufort County, South Carolina, the eleventh child of a sharecropping family. [D]
- As a teenager he moved to Philadelphia, where he had relatives, and worked in a slaughterhouse, where he punched sides of beef in the cold room. [D]
- He won the heavyweight gold medal at the 1964 Olympic Games in Tokyo, fighting the final with a broken left thumb. [D]
- Later in 1964 he learned that he had a cataract in his left eye; visually impaired, he turned professional anyway. The cataract grew worse, and by 1975, according to his eye doctor, his vision was 20/50 in the right eye and 20/400 in the left. [D]
- He became undisputed world heavyweight champion in February 1970 and held the title until January 1973, defending it four times; he retired in 1976 after a professional record of 32 wins, 4 losses and 1 draw, with 27 knockouts, and returned for a single bout in 1981. [D]
- His three-fight rivalry in the 1970s included a 1971 victory that handed his opponent his first professional defeat; in the third fight, in Manila in 1975, he could no longer see, and his trainer would not let him come out for the fifteenth round. [D]
- In later life he lived in Philadelphia, where he owned and ran a boxing gym, and he had financial trouble. [D]
- During his life it was reported publicly that he had diabetes and high blood pressure. [D]
- He published an autobiography, Smokin' Joe, in 1996. [D]
2 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years | One tablet twice daily with meals | Oral route | 2008-02-16 | active | S |
| Lisinopril 20 mg oral tablet, one tablet daily; taken for years | One tablet daily | Oral route | 2008-02-16 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2008-02-16 | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetes | active | confirmed |
E11.65 | S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic. |
| Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressure | active | confirmed |
I10 | S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life. |
| Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluated | active | confirmed |
R74.01 | S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis. |
| Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statin | active | confirmed |
E78.5 | S — Synthetic laboratory finding. |
| Obesity, class 1 (BMI 31.4) | active | confirmed |
E66.811 | S — Synthetic finding; described without stigma. |
| Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30 | active | confirmed |
H54.62 | S — Synthetic modern measurement anchored to the documented cataract in his left eye. |
Past Medical History
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|
| 1964 | Broken left thumb in the 1964 Olympic final | D (CLM-0003) |
| 1964 | Cataract in the left eye found at 20, with reduced vision in that eye through his boxing career (20/400 in that eye by 1975) | D (CLM-0004) |
| 1965 to 1976, and one bout in 1981 | Professional heavyweight boxing career with many blows to the head, including a 1975 bout stopped when he could no longer see | D (CLM-0005, CLM-0006) |
| early 2000s | Diabetes and high blood pressure, reported publicly | D (CLM-0008) |
Family History
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
Social History
- Former professional heavyweight boxer and Olympic champion; owns and runs a boxing gym in Philadelphia, where he trains young fighters most days [S]
- Grew up on a farm in South Carolina; moved to Philadelphia as a teenager and worked in a slaughterhouse [S]
- Money is tight; worries about the cost of medicines and appointments; prefers generics and 90-day supplies [S]
- Alcohol: one or two beers on some weekends (AUDIT-C 2); no other drug use [S]
- Tobacco: never [S]
- Activity: on his feet at the gym most of the day and holds pads for his fighters; no longer runs because of his knees [S]
- Strengths: discipline, pride in his work, the young fighters who rely on him, his faith, and a long habit of showing up [S]
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 2008-02-16 | Body height | 182 | cm | S |
| 2008-02-16 | Body weight | 104 | kg | S |
| 2008-02-16 | Body mass index (BMI) [Ratio] | 31.4 | kg/m2 | S |
| 2008-02-16 | Systolic blood pressure | 152 | mm[Hg] | S |
| 2008-02-16 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 2008-02-16 | Heart rate | 76 | /min | S |
| 2008-02-16 | Respiratory rate | 16 | /min | S |
| 2008-02-16 | Body temperature | 36.7 | Cel | S |
| 2008-02-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2008-02-16 | Hemoglobin A1c/Hemoglobin.total in Blood | 8.4 | % | Below 5.7% is normal; goal below 7% for him | High | S |
| 2008-02-16 | Glucose [Mass/volume] in Serum or Plasma | 168 | mg/dL | 70-99 mg/dL | High | S |
| 2008-02-16 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2008-02-16 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2008-02-16 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2008-02-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2003)/1.73 sq M | 77 | mL/min/{1.73_m2} | 60 or higher without kidney damage markers is not CKD | Normal | S |
| 2008-02-16 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | Below 30 mg/g is normal (A1) | Normal | S |
| 2008-02-16 | Cholesterol [Mass/volume] in Serum or Plasma | 212 | mg/dL | <=199 mg/dL | High | S |
| 2008-02-16 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 132 | mg/dL | Goal below 70 mg/dL with diabetes and other risk factors | High | S |
| 2008-02-16 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 38 | mg/dL | >=40 mg/dL | Low | S |
| 2008-02-16 | Triglyceride [Mass/volume] in Serum or Plasma | 210 | mg/dL | <=149 mg/dL | High | S |
| 2008-02-16 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 | U/L | 10-40 U/L | High | S |
| 2008-02-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 42 | U/L | 7-55 U/L | Normal | S |
| 2008-02-16 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 | U/L | 40-129 U/L | Normal | S |
| 2008-02-16 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2008-02-16 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2008-02-16 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2008-02-16 | Platelets [#/volume] in Blood by Automated count | 138 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2008-02-16 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 340 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2008-02-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | | | S |
| 2008-02-16 | Total score [AUDIT-C] | 2 | {score} | | | S |
Assessment
- Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetes: active, confirmed [S]
- Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressure: active, confirmed [S]
- Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluated: active, confirmed [S]
- Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statin: active, confirmed [S]
- Obesity, class 1 (BMI 31.4): active, confirmed [S]
- Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30: active, confirmed [S]
Plan of Treatment
- Diabetes: continue metformin, an A1c every three months until at goal and then every six months, diabetes self-management education, a vitamin B12 check on long-term metformin, and no medicine that causes low blood sugar. Guideline: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) [S]
- Liver assessment: FIB-4 from the yearly liver tests, then transient elastography if FIB-4 is 1.3 or higher; hepatitis B, hepatitis C and HIV tests, iron studies, and an alcohol history. Guideline: 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) [S]
- Blood pressure: a validated home monitor with a large cuff, readings twice a day for a week, a goal below 130/80 mmHg, and less salt. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) [S]
- Cardiovascular risk: atorvastatin 40 mg with a lipid panel at four to twelve weeks; a baseline ECG; aspirin for primary prevention not used because of bleeding risk. Guideline: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) [S]
- Kidneys: eGFR by the race-free CKD-EPI 2003 equation and urine albumin-to-creatinine ratio at least yearly, and potassium and creatinine on lisinopril. Guideline: 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) [S]
- Eyes and feet: a dilated eye examination at the eye clinic, a comprehensive foot examination yearly, daily foot checks and callus care. Guideline: 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026) [S]
- Brain health: a documented cognitive screen at the preventive visit, blood pressure and glucose control, sleep, hearing and mood checks, and an honest conversation that chronic traumatic encephalopathy cannot be diagnosed during life. Guideline: National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) [S]
- Cost and access: low-cost generics, 90-day supplies, and help with coverage for any brand-name medicine. Guideline: 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026) [S]
- Referral to hepatology, Anjali Deshpande, MD, ordered 2008-02-16 [S]